deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01701986

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas

Sponsor: M.D. Anderson Cancer Center

Conditions Hematopoietic Cell Transplantation Recipient Refractory B-Cell Non-Hodgkin Lymphoma Refractory Hodgkin Lymphoma Refractory T-Cell Non-Hodgkin Lymphoma
Interventions Allogeneic Bone Marrow Transplantation Allogeneic Hematopoietic Stem Cell Transplantation Anti-Thymocyte Globulin Busulfan Clofarabine Gemcitabine Hydrochloride Mycophenolate Mofetil Peripheral Blood Stem Cell Transplantation Pharmacological Study Rituximab Tacrolimus
Updated 18 times since 2017 Last updated: Feb 7, 2025 Started: Oct 25, 2012 Primary completion: Jun 5, 2024 Completion: Jun 5, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01701986, this PHASE1/PHASE2 trial focuses on Hematopoietic Cell Transplantation Recipient and Refractory B-Cell Non-Hodgkin Lymphoma and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 18 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2018 · 15 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Dec 2019 · 6 months · monthly snapshot~Dec 2019 – ~Aug 2020 · 8 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Sep 2023 · 6 months · monthly snapshot~Sep 2023 – ~Mar 2024 · 6 months · monthly snapshot~Mar 2024 – ~Jun 2024 · 3 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – present · 16 months · monthly snapshot

Change History

18 versions recorded

  1. Mar 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Mar 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 13 earlier versions

  1. Sep 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Mar 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Sep 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Dec 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Feb 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Dec 2019 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  12. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations